Replies to post #240415 on Biotech Values

[kris_kade]

Dew, you think GAI score (1-point reduction) across different intervals is not good enough ? Thanks

[DewDiligence]

DRMA -58% on phase-2 failure in rosacea:

https://finance.yahoo.com/news/dermata-announces-topline-results-dmt310-133000446.html

I normally wouldn’t post about a company with a market cap of <$10M, but I have a special interest in DRMA because they previously claimed to have positive data for a topical botulinum toxin (#msg-166847151). The drug candidate in that PR, DMT410, is no longer in the company’s pipeline, LOL.